Ultragenyx Pharmaceutical Inc.
UX701
Wilson disease
Countdown
177days
Phase 3 readout · ~ Dec 31, 2026 estimated
What's at stake
Phase 3 trial results for UX701 in Wilson disease are due ~ Dec 31, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 14h ago
“Data from this stage are expected in 2026.”